#USA #Rockville #gene therapy #AAVnerGene #AAVone®2.1

AAVnerGene Launches AAVone®2.1: The Future of AAV Production

AAVnerGene Inc., a Maryland-based biotech company, has recently introduced AAVone®2.1, an innovative platform designed for the production of adeno-associated virus (AAV) vectors. This cutting-edge system is built to address the challenges associated with the commercial-scale production of AAV-based gene therapies, marking a significant advancement over previous methods.

Enhanced Productivity and Efficiency

The latest iteration, AAVone®2.1, achieves impressive ~1e16 genome copies per liter (GC/L) and over 70% full capsids at harvest. These results show a remarkable improvement over the company's earlier product, AAVone®1.0, and also outperform traditional multi-plasmid systems that are often encumbered by a high proportion of empty capsids.

This new production system has demonstrated its efficacy across various AAV serotypes and features compatibility with HEK293-based cell lines, which are widely used in current manufacturing processes. The optimizations included in the AAVone®2.1 platform are expected to substantially reduce the need for plasmids and cell culture volume, as well as the complexities involved in cleaning and processing, thereby lowering production costs while simultaneously enhancing the quality of the viral vectors produced.

Addressing Challenges in Gene Therapy

The AAV production process is one of the critical hurdles in the expansion of gene therapy applications. According to Qizhao Wang, Ph.D., the Chief Technology Officer of AAVnerGene, conventional systems have been instrumental in advancing this field but are still plagued by limitations in productivity and challenges regarding empty capsid load and purification complexity. AAVone®2.1 aims to simplify these issues by integrating a streamlined single-plasmid system that enhances vector yield and capsid quality.

Daozhan Yu, Ph.D., the Chief Executive Officer of AAVnerGene, elaborated on the significance of this development. He pointed out that factors such as production costs, vector quality, and scalability are crucial for the commercialization of AAV gene therapies. AAVone®2.1 promises to make AAV manufacturing not only easier but also more scalable and cost-effective, thereby supporting more AAV-based therapy programs from clinical phases to commercial viability.

Collaborations and Future Prospects

AAVnerGene's partners are already leveraging this new technology to advance multiple AAV gene therapy programs. The company's vision is to provide solutions that dismantle manufacturing barriers, reduce development costs, and increase the number of gene therapy programs that can ultimately benefit patients.

With platforms like AAVone®, AAV-Q (a potency and rcAAV assay platform), and ATHENA (a capsid engineering platform), AAVnerGene is uniquely positioned to lead advancements in the productivity, quality, efficiency, and safety of AAV gene therapies.

For further information about AAVnerGene and their novel AAV production solutions, visit AAVnerGene's website. They aim to contribute significantly to the gene therapy landscape by ensuring that innovative solutions reach those who need them most.